ICAM1 and neoplasm: To further dissect the involvement of tumor ICAM-1 in an antitumor immune response elicited by antitumor CTLs, we next tested if monoclonal effector CTLs specific for the OVA neoantigen introduced into E0771 cells can eliminate these cancer cells in vitro and in vivo in an ICAM-1-facilitated manner.